Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials. J of Skin. 2023;7(2):s129. doi:10.25251/skin.7.supp.129